简体中文

Newsroom

News

May 20, 2021

BIG EVENETS. Day 1 | Biofuture 2021


Biofuture 2021 Next-Generation Antibody Drug Technology Innovation Conference & AMP held in Crowne Plaza Shanghai on May 19, 2021, at 9:00 a.m.; Cell and gene therapy innovation meeting began Biological medicine industry as one of the major industries of the future economic development which is also full of opportunities and challenges. The conference was mainly discussed the antibody-drug of opportunities and challenges, antibody-drug innovation development and production process, optimization cells new breakthrough in gene therapy, gene therapy industry innovation as well as commercialization.



Quacell Biotech will meet you all at booth #B21


The products that will bring to this exhibition are the popular product of Quacell biotech including the QuamonoTM Plus monoclonal culture medium, and viral packaging host HEK293/293T cell line. QuamonoTM Plus monoclonal culture medium has the characteristics of shortening the multiplication time of CHO monoclonal cells and quickly screening out highly expressed monoclonal strains.


As the exclusive sub-licensee of the HEK293/293T cell line in China, Quacell can also provide the global commercial license of the HEK293/293T cell line to domestic enterprises. Quacell has a high-standard domestic cell bank, which can exempt the application of import customs declaration and quickly deliver goods from stock. It can solve the problems of traceability and authorization of host cell lines at one time, and help the field of cell and gene therapy, and empower domestic partners.





Dr Pan Honghui, CEO of Quacell Biotechnology, and Mr Wu Fan, COO of Quacell Biotechnology, members of Quacell and colleagues had a heated discussion with the guests about the product characteristics, cell proliferation effect and application system of Quamono ™ Plus monoclonal medium, as well as the product characteristics and project application of HEK293/293T cell line. Everyone expressed their own opinions.


Dr Pan Honghui, CEO of Quacell, delivered a speech titled "Development and commercialization of HEK293 cell line with high-efficiency virus packaging" at the Cell and Gene Therapy Innovation Conference at 14:45-15:10 on the 19th afternoon. There were huge among of the audience attended to this conference and gave a great response.  The end of the sub-forum speech on MAY 19th has come to an end at around 18 PM in the afternoon. Let's meet at the #B21 booth on May 20th to continue our discussion about the application of Quamono ™ Plus monoclonal medium and HEK293 cell line. Be there or be square!



Latest Articles